IUATLD - North American Region, Chicago, IL. March 2001
Hirsch-Moverman Y, Daud A, Gee
V, Nader N, Colson PW, El-Sadr W. Treatment Preferences
And Attitudes Among Patients Screened For Latent TB Infection
Treatment of Latent Tuberculosis Infection (LTBI) has traditionally
involved 6 - 12 mos of isoniazid (INH). Shorter course regimens
(RIF/PZA for 2 mos) have recently been offered but involve
more pills and potentially side effects. Little is known about
patient preferences for these LTBI regimens.
We assessed patients' demographics, treatment preferences,
and TB knowledge & attitudes in Harlem. The preferences
portion included 6 factors relating to treatment preferences,
a presentation of two treatment options for LTBI treatment,
treatment preference and reason for it. The K&A section
included 24 items testing knowledge, and 26 items examining
Of 69 patients, 81% were African-American, 9% Latino, 30%
foreign-born, mean age of 38 years, 41% had a history of homelessness,
54% had completed high school, and 10% were previously treated
for LTBI. Fifty five percent of patients preferred the short-course
treatment. Those who preferred the longer treatment tended
to highlight fewer side effects (55%) and fewer pills (39%),
while those who preferred shorter-course regimens emphasized
short duration (92%). There was no difference in the TB Knowledge
scores between INH group (16.0) and RIF/PZA group (16.2).
RIF/PZA group perceived LTBI treatment as a hassle (30% vs.
3%, p=0.008), and reported shunning medical care when feeling
sick (29% vs. 10%, p=0.073).
Different patients emphasized various factors in their preference
for LTBI regimen. Findings suggest that shorter-course regimen
may be especially suited to those likely to default treatment.